Vor Biopharma Inc (VOR) concluded trading on Wednesday at a closing price of $2.09, with 5.5 million shares of worth about $11.5 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 53.68% during that period and on July 23, 2025 the price saw a gain of about 1.95%. Currently the company’s common shares owned by public are about 124.85M shares, out of which, 64.90M shares are available for trading.
Stock saw a price change of -1.42% in past 5 days and over the past one month there was a price change of 620.69%. Year-to-date (YTD), VOR shares are showing a performance of 126.36% which increased to 88.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.29 during that period. The average intraday trading volume for Vor Biopharma Inc shares is 18.03 million. The stock is currently trading 7.54% above its 20-day simple moving average (SMA20), while that difference is up 131.96% for SMA50 and it goes to 124.86% higher than SMA200.
Vor Biopharma Inc (NASDAQ: VOR) currently have 124.85M outstanding shares and institutions hold larger chunk of about 42.12% of that.
The stock has a current market capitalization of $261.17M and its 3Y-monthly beta is at 2.06. It has posted earnings per share of -$1.51 in the same period. It has Quick Ratio of 3.88 while making debt-to-equity ratio of 0.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VOR, volatility over the week remained 13.71% while standing at 35.09% over the month.
Stock’s fiscal year EPS is expected to rise by 56.45% while it is estimated to increase by 36.23% in next year. EPS is likely to grow at an annualized rate of 18.66% for next 5-years, compared to annual growth of -38.02% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 30, 2025 offering a Buy rating for the stock and assigned a target price of $3 to it. Coverage by Wedbush stated Vor Biopharma Inc (VOR) stock as an Outperform in their note to investors on July 26, 2022, suggesting a price target of $18 for the stock. On April 27, 2022, Goldman Initiated their recommendations, while on December 17, 2021, H.C. Wainwright Initiated their ratings for the stock with a price target of $26. Stock get an Outperform rating from Robert W. Baird on December 03, 2021.
